- Report
- May 2022
- 510 Pages
Global
From €2892EUR$3,000USD£2,474GBP
- Report
- December 2020
- 120 Pages
Global
From €1928EUR$2,000USD£1,649GBP
- Report
- November 2018
- 161 Pages
Global
From €1326EUR$1,375USD£1,134GBP
€2651EUR$2,750USD£2,267GBP
- Report
- March 2022
- 175 Pages
Global
From €1919EUR$1,990USD£1,641GBP
- Report
- April 2024
- 180 Pages
From €4724EUR$4,900USD£4,040GBP
- Report
- July 2022
- 199 Pages
Global
From €3071EUR$3,185USD£2,626GBP
€4387EUR$4,550USD£3,752GBP
- Report
- April 2023
- 117 Pages
Global
From €4579EUR$4,750USD£3,917GBP
- Report
- August 2022
- 115 Pages
Global
From €4579EUR$4,750USD£3,917GBP
- Report
- January 2022
- 121 Pages
Global
From €4579EUR$4,750USD£3,917GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2651EUR$2,750USD£2,267GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2651EUR$2,750USD£2,267GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €3133EUR$3,250USD£2,680GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2651EUR$2,750USD£2,267GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €3133EUR$3,250USD£2,680GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €3133EUR$3,250USD£2,680GBP
- Drug Pipelines
- September 2022
- 30 Pages
Global
From €3133EUR$3,250USD£2,680GBP
- Report
- January 2022
- 60 Pages
Global
From €3808EUR$3,950USD£3,257GBP
- Report
- January 2022
- 200 Pages
Global
From €7231EUR$7,500USD£6,184GBP
- Report
- January 2022
- 125 Pages
Global
From €1928EUR$2,000USD£1,649GBP
- Report
- January 2022
- 200 Pages
Global
From €7231EUR$7,500USD£6,184GBP
The Lung Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat lung cancer. These drugs are used to treat both non-small cell and small cell lung cancer, the two most common types of lung cancer. The drugs are designed to target the cancer cells and stop them from growing and spreading. Common treatments include chemotherapy, targeted therapy, immunotherapy, and radiation therapy.
The Lung Cancer Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Companies such as Bristol-Myers Squibb, Merck, Pfizer, AstraZeneca, and Roche are all major players in the market. These companies are constantly researching and developing new drugs to treat lung cancer, as well as improving existing treatments.
In addition, there are many smaller companies that specialize in the development of new drugs for the treatment of lung cancer. These companies often collaborate with larger pharmaceutical companies to bring their drugs to market. Examples of these companies include ImmunoGen, Inc., Oncolytics Biotech, and ImmunoCellular Therapeutics. Show Less Read more